European pricing and reimbursement policies

2020: USTR takes aim at Europe over pharmaceutical pricing and reimbursement policies

On 31 March 2020, the Office of the United States Trade Representative (USTR) published its 2020 National Trade Estimates Report on Foreign Trade Barriers (NTE). As USTR notes, in “accordance with section 181 of the Trade Act of 1974, as amended by section 303 of the Trade and Tariff Act of 1984 and amended by …

2020: USTR takes aim at Europe over pharmaceutical pricing and reimbursement policies Read More »

KEI Europe comments on the EU’s cancer roadmap

KEI Europe response to the European Union’s cancer roadmap 3 March 2020 Cell and gene therapies are among the more promising innovations to treat cancer. Chimeric Antigen Receptor T-Cell (“CAR T” or “CAR T-cell”) treatments involve a combination of  procedures that take place both in and outside of the body. Blood is taken from a …

KEI Europe comments on the EU’s cancer roadmap Read More »

2019: USTR takes aim at European countries over pharmaceutical pricing and reimbursement policies

On 29 March 2019, the Office of the United States Trade Representative (USTR) published its 2019 National Trade Estimates Report on Foreign Trade Barriers (NTE). Every year, the USTR is tasked with submitting to the “President, the Senate Finance Committee, and appropriate committees in the House of Representatives, an annual report on significant foreign trade …

2019: USTR takes aim at European countries over pharmaceutical pricing and reimbursement policies Read More »